Bisphosphonate-related osteonecrosis of the jaw (BRONJ) in cancer patients

Cover Page

Cite item

Full Text

Abstract

This literature review focuses on the latest advances in the study of osteonecrosis of the jaw in cancer patients taking bisphosphonates. Prescribing bisphosphonates for the treatment of metastatic bone disease is justifiable and unavoidable measure. The action of bisphosphonates leads to increase in bone tissue strength, but significantly suppressing normal bone remodelling, essential for repair, and becomes vulnerable to mechanical trauma and bacterial invasion. The unique anatomical and physiological features of the jaw bones determine their selective damage. The disease is characterized by progressive jaw necrosis, chronic inflammation of the surrounding tissues complicated by a pathological fracture and persistent oroantral fistula, which aggravates chronic pain and leads to a deterioration in the quality of life of patients. The occurrence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a multifactorial process. Most often, it occurs in patients with long term treatment with zoledronic acid preparations against after tooth extraction. The fact of an increase in the incidence of osteonecrosis is undeniable for objective reasons, the main of which are an increase in cancer, an increase in the life expectancy of cancer patients and their need for bisphosphonate therapy. In the article, it was analyzed the latest scientific reports on the causes of the disease, risk factors and the pathogenesis of the disease. Data on the frequency of jaw osteonecrosis in different countries are presented. It was shown promising developments and summarizes information on existing methods for diagnosing jaw bisphosphonate osteonecrosis. Questions about the key approaches in the treatment of the disease, as well as about new experimental techniques, are examined. The main problems of the prevention of bisphosphonate-related osteonecrosis of the jaws are formulated.

About the authors

A K Ebzeev

Stavropol State Medical University

Author for correspondence.
Email: ebzeev89@list.ru
Russian Federation, Stavropol, Russia

References

  1. Manzyuk L.V., Bagrova S.G., Kopp M.V. et al. The use of osteomodifying agents for the prevention and treatment of bone tissue pathology in malignant neoplasms. Zlokachestvennye opukholi. Prakticheskie rekomenda­tsii RUSSCO. 2017; 7 (3 S2): 477–485. (In Russ.) doi: 10.18027/2224-5057-2017-7-3s2-477-485.
  2. Bolshakova S.A., Bychkov Y.M. Modern treatment of breast cancer bone metastases: from bisphosphonates to targeted therapy. Vestnik Rossiyskogo nauchnogo tsentra rentgenoradiologii Minzdrava Rossii. 2016; 16 (4): 1–28. (In Russ.)
  3. Leng S., Chen Y., Tsai W.Y. et al. Use of bisphosphonates in elderly patients with newly diagnosed multiple mye­loma. J. Natl. Compr. Canc. Netw. 2019; 17 (1): 22–28. doi: 10.6004/jnccn.2018.7079.
  4. Ruggiero S.L., Dodson T.B., Fantasia J. et al. Ame­rican Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw — 2014 update. J. Oral Maxillofac. Surg. 2014; 72 (10): 1938–1956. doi: 10.1016/j.joms.2014.04.031.
  5. McGowan K., Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Diseases. 2018; 24 (4): 527–536. doi: 10.1111/odi.12708.
  6. Khan A.A., Morrison A., Kendler D.L. et al. Case-based review of Osteonecrosis of the Jaw (ONJ) and application of the International recommendations for ma­nagement from the International Task Force on ONJ. J. Clin. Densitom. 2017; 20 (1): 8–24. doi: 10.1016/­j.jocd.­2016.09.005.
  7. Shibahara T., Morikawa T., Yago K. et al. National survey on bisphosphonate-related osteonecrosis of the jaws in Japan. J. Oral Maxillofac. Surg. 2018; 76 (10): 2105–2112. doi: 10.1016/j.joms.2018.04.009.
  8. Cuevas-González M.V., Díaz-Aguirre С.M., Echevarría-Y-Pérez E., Cuevas-González J.C. Prevalence of osteonecrosis of the jaw and oral characteristics of oncologic patients treated with bisphosphonates at the General Hospital of Mexico. J. Korean Assoc. Oral Maxillofac. Surg. 2016; 42 (6): 365–369. doi: 10.5125/jkaoms.2016.42.6.365.
  9. Hallmer F., Andersson G., Götrick B. et al. Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2018; 126 (6): 477–485. doi: 10.1016/j.oooo.2018.08.015.
  10. Di Fede O., Panzarella V., Mauceri R. et al. The dental management of patients at risk of medication-rela­ted osteonecrosis of the jaw: New paradigm of primary prevention. Biomed. Res. Int. 2018, 16; 2018: 2684924. doi: 10.1155/2018/2684924.
  11. Tardast A., Sjoman R., Loes S., Abtahi J. Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking. J. Appl. Oral Sci. 2015; 23 (3): 310–314. doi: 10.1590/1678-775720140506.
  12. Dodson T.B. The frequency of medication-rela­ted osteonecrosis of the jaw and its associated risk factors. Oral Maxillofac Surg Clin North Am. 2015; 27 (4): 509–516. doi: 10.1016/j.coms.2015.06.003.
  13. Panya S., Fliefel R., Probst F. et al. Role of microbiological culture and polymerase chain reaction (PCR) of actinomyces in medication-related osteonecrosis of the jaw (MRONJ). J. Craniomaxillofac. Surg. 2017; 45 (3): 357–363. doi: 10.1016/j.jcms.2017.01.006.
  14. Vinogradova N.G., Lʹvov K.V., Kharitonova M.P. Prevalence and clinical features of drug-related osteonecroses of the jaws. Problemy stomatologii. 2017; 13 (4): 38–42. (In Russ.) doi: 10.18481/2077-7566-2017-13-4-38-42.
  15. Zhuravleva M.V., Zhuravlev L.V., Firsova I.V. Actual view on the problem of bisphosphonate related jaw osteonecrosis. Zdorovʹe i obrazovanie v XXI veke. 2018; 20 (5): 88–92. (In Russ.) doi: 10.26787/nydha-2226-7425-2018-20-5-88-92.
  16. Gross C., Weber M., Creutzburg K. et al. Osteoclast profile of medication-related osteonecrosis of the jaw se­condary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis. J. Transl. Med. 2017; 15 (1): 128. doi: 10.1186/s12967-017-1230-8.
  17. Wehrhan F., Gross C., Creutzburg K. et al. Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication-related osteonecrosis of the jaw se­condary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis. J. Transl. Med. 2019; 17 (1): 69. doi: 10.1186/s12967-019-1819-1.
  18. Yoneda T., Hagino H., Sugimoto T. et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J. Bone Miner. Metab. 2017; 35 (1): 6–19. doi: 10.1007/s00774-016-0810-7.
  19. Kim S.M., Eo M.Y., Kim Y.S., Lee S.K. Histochemical observation of bony reversal lines in bisphosphonate-related osteonecrosis of the jaw. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2017; 123 (2): 220–228. doi: 10.1016/­j.oooo.2016.09.225.
  20. Reva I.V., Reva G.V., Tolmachev V.E. et al. Mechanisms of osteonecrosis of the jaw in multiple myeloma. Sovremennye problemy nauki i obrazovaniya. 2015; 5: 167. (In Russ.)
  21. Devlin H., Greenwall-Cohen J., Benton J. et al. Detecting the earliest radiological signs of bisphosphonate-­related osteonecrosis. Br. Dent. J. 2018; 224: 26–31. doi: 10.1038/sj.bdj.2017.1001.
  22. Zhukova N.A. Staging of bisphosphonate-related osteonecrosis of the jaws inpatients with malignant tumors according multislice computed tomography. Meditsinskaya vizualizatsiya. 2016; (3): 17–27. (In Russ.)
  23. Goller-Bulut D., Ozcan G., Avci F. Changes in dimension of neurovascular canals in the mandible and ma­xilla: A radiographic finding in patients diagnosed with MRONJ. Med. Oral Patol. Oral Cir. Bucal. 2018; 23 (3): 282–289. doi: 10.4317/medoral.22274.
  24. Kitagawa Y., Ohga N., Asaka T. et al. Imaging modalities for drug-related osteonecrosis of the jaw (3), Posi­tron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw. Jpn. Dent. Sci. Rev. 2019; 55 (1): 65–70. doi: 10.1016/j.jdsr.2018.12.001.
  25. Valieva M.M., Nesterov O.V., Urakova E.V. et al. Early diagnosis of bisphosphonate-related osteonecroses of a jaw. Prakti­cheskaya meditsina. 2018; (7-2): 26–29. (In Russ.)
  26. Sletov A.A., Mikhalʹchenko D.V., Zhidovinov A.V. et al. Diagnostics and forecasting of surgical treatment of patients with osteonecrosis and aseptic osteomyelitis of the maximum bone. Krymskiy terapevticheskiy zhurnal. 2018; (1): 73–77. (In Russ.)
  27. Manea H.C., Urechescu H.C., Balica N.C. Bisphosphonates-induced osteonecrosis of the jaw — epidemiolo­gical, clinical and histopathological aspects. Rom. J. Morphol. Embryol. 2018; 59 (3): 825–831. PMID: 30534822.
  28. Hallmer F., Bjornland T., Andersson G. et al. Bacterial diversity in medication-related osteonecrosis of the jaw. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. 2017; 123 (4): 436–444. doi: 10.1016/j.oooo.2016.11.011.
  29. Poxleitner P., Engelhardt M., Schmelzeisen R., Voss P. The prevention of medication-related osteonecrosis of the jaw. Dtsch. Arztebl. Int. 2017; 114 (5): 63–69. doi: 10.3238/arztebl.2017.0063.
  30. Spevak E.M., Khristoforando D.Yu., Davydov A.B. Assessment of bone meta­bolism in patients with bisphosphonate osteonecrosis of the jaws. Rossiyskiy stomatologicheskiy zhurnal. 2017; 21 (4): 197–199. (In Russ.) doi: 10.18821/1728-2802-2017-21-4-197-199.
  31. Shin W.J., Kim C.H. Prognostic factors for outcome of surgical treatment in medication-related osteonecrosis of the jaw. J. Korean Assoc. Oral Maxillofac. Surg. 2018; 44 (4): 174–181. doi: 10.5125/jkaoms.2018.44.4.174.
  32. Zirk M., Kreppel M., Buller J. et al. The impact of surgical intervention and antibiotics on MRONJ stage II and III — Retrospective study. J. Craniomaxillofac. Surg. 2017; 45 (8): 1183–1189. doi: 10.1016/j.jcms.2017.05.027.
  33. Bermúdez-Bejarano E.B., Serrera-Figallo M.A., Gutiérrez-Corrales A. et al. Prophylaxis and antibiotic the­rapy in management protocols of patients treated with oral and intravenous bisphosphonates. J. Clin. Exp. Dent. 2017; 9 (1): 141–149. doi: 10.4317/jced.53372.
  34. Lopes R.N., Rabelo G.D., Rocha A.C. et al. Surgical therapy for bisphosphonate-related osteonecrosis of the jaw: six-year experience of a single institution. J. Oral Maxillofac. Surg. 2015; 73: 1288–1295. doi: 10.1016/j.joms.2015.01.008.
  35. Caldroney S., Ghazali N., Dyalram D., Lubek J.E. Surgical resection and vascularized bone reconstruction in advanced stage medication-related osteonecrosis of the jaw. Int. J. Oral Maxillofac. Surg. 2017; 46 (7): 871–876. doi: 10.1016/j.ijom.2017.01.023.
  36. García-de Marcos J.A., Rey-Biel J. Submental perforator flap for soft-tissue reconstruction in bisphosphonate-related osteonecrosis of the jaws. Craniomaxillofac. Trauma Reconstr. 2017; 10 (4): 299–305. doi: 10.1055/s-0036-1593472.
  37. Otto S., Ristow O., Pache C. et al. Fluorescence-guided surgery for the treatment of medication-­related osteonecrosis of the jaw: A prospective cohort study. J. Craniomaxillofac. Surg. 2016; 44 (8): 1073–1080. doi: 10.1016/j.jcms.2016.05.018.
  38. Poli P.P., Souza F.A., Maiorana C. Adjunctive use of antimicrobial photodynamic therapy in the treatment of medication-related osteonecrosis of the jaws: A case report. Photodiagnosis Photodyn. Ther. 2018; 23: 99–101. doi: 10.1016/j.pdpdt.2018.06.004.
  39. Procacci P., Albanese M., Trevisiol L. et al. Medication-related osteonecrosis of the posterior maxilla: surgical treatment using a combined transnasal endoscopic and intraoral approach, our experience with seven consecutive patients. Clin. Otolaryngol. 2018; 43 (2): 685–691. doi: 10.1111/coa.12999.
  40. Laimer J., Steinmassl O., Hechenberger M. et al. Intraoral vacuum-assisted closure therapy — A pilot study in medication-related osteonecrosis of the jaw. J. Oral Ma­xillofac. Surg. 2017; 75 (10): 2154–2161. doi: 10.1016/j.joms.2017.02.033.
  41. Blus C., Giannelli G., Szmukler-Moncler S., Orru G. Treatment of medication-related osteonecrosis of the jaws (MRONJ) with ultrasonic piezoelectric bone surgery. A case series of 20 treated sites. Oral Maxillofac. Surg. 2017; 21 (1): 41–48. doi: 10.1007/s10006-016-0597-7.
  42. Voss P.J., Matsumoto A., Alvarado E. et al. Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells. Odontology. 2017; 105 (4): 484–493. doi: 10.1007/s10266-017-0295-4.
  43. Del Fabbro M., Gallesio G., Mozzati M. Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature. Eur. J. Cancer. 2015; 51 (1): 62–74. doi: 10.1016/j.ejca.2014.10.015.
  44. Momesso G.A., de Souza Batista F.R., de Sousa C.A. et al. Successful use of lower-level laser therapy in the treatment of medication-related osteonecrosis of the jaw. J. Lasers Med. Sci. 2017; 8 (4): 201–203. doi: 10.15171/jlms.2017.37.
  45. Makeeva I.M., Volkov A.G., Dikopova N.Zh. et al. Treatment of bisphosphonate necrosis of the jaws with ozone obtained by ultraviolet irradiation. Head and neck. 2017; (3): 73–75. (In Russ.)
  46. Owosho A.A., Estilo C.L., Huryn J.M. et al. Pento­xifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2016; 122 (4): 455–459. doi: 10.1016/j.oooo.2016.06.019.
  47. Petrosyan A.L., Kutukova S.I., Chefu S.G. et al. Sulodexide as a choice of prevention of bisphosphonate osteonecrosis. Smolenskiy meditsinskiy alʹmanakh. 2018; (4): 118–120. (In Russ.)
  48. Kakehashi H., Ando T., Minamizato T. et al. Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings. Int. J. Oral Maxillofac. Surg. 2015; 44 (12): 1558–1564. doi: 10.1016/j.ijom.2015.07.018.
  49. Bedogni A., Bettini G., Bedogni G. et al. Is vitamin D deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? A matched case-control study. J. Craniomaxillofac. Surg. 2019; 47 (8): 1203–1208. doi: 10.1016/j.jcms.2019.03.007.
  50. Hayashida S., Soutome S., Yanamoto S. et al. Eva­luation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affec­ting treatment outcome: a multicenter retrospective study with propensity score matching analysis. J. Bone Miner. Res. 2017; 32: 2022–2029. doi: 10.1002/jbmr.3191.
  51. McDonnell F., Steel C. The importance of dental screening prior to commencing anti-resorptive therapy for treatment of cancer: A case report and discussion. Prim. Dent. J. 2018; 7 (3): 42–45. PMID: 30428967.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

© 2020 Ebzeev A.K.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».